Huahai Pharmaceutical(600521) announced on March 19 that its subsidiary, Shanghai Huaaotai Biotechnology Co., Ltd.Following the completion of the Phase II clinical trial and the pre-initiation meeting for the Phase III clinical trial with the Center for Drug Evaluation of the National Medical Products Administration, the company's independently developed HB0025 injection will officially commence Phase III clinical trials for advanced/recurrent endometrial cancer. This trial will primarily evaluate the therapeutic efficacy, safety, and tolerability of HB0025 in combination with chemotherapy. To date, the company's total R&D investment in the HB0025 project is approximately RMB 342 million.

According to the announcement, HB0025 is an innovative anti-PD-L1/VEGF bispecific fusion protein that simultaneously targets the tumor immune escape pathway PD-L1 and the tumor angiogenesis pathway VEGF, possessing a dual anti-tumor mechanism of "immune enhancement + anti-angiogenesis". Currently, there are no completely similar products on the market domestically or internationally. The development of this product will help enrich the company's product pipeline in the field of oncology treatment and enhance its core competitiveness.

Currently, multiple clinical trials of HB0025 are underway, covering various solid tumors such as squamous and non-squamous non-small cell lung cancer, endometrial cancer, colorectal cancer, and triple-negative breast cancer.

https://finance.eastmoney.com/a/202603193677057524.html